Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.44 |
| ▸ | MERTK | Q12866 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909782 | 1.00 | BRAF (0.52) | BRAFFLT3AXLTYRO3MERTK | |
| SCHEMBL9909781 | 0.86 | BRAF (0.51) | BRAFFLT3 | |
| SCHEMBL30462276 | 0.86 | BRAF (0.51) | BRAFFLT3 | |
| SCHEMBL3756201 | 0.85 | BRAF (0.60) | BRAF | |
| SCHEMBL2935823 | 0.84 | BRAF (0.70) | BRAF | |
| SCHEMBL24802203 | 0.83 | BRAF (0.64) | BRAF | |
| SCHEMBL30814305 | 0.83 | BRAF (0.64) | BRAF | |
| SCHEMBL3762183 | 0.82 | BRAF (0.67) | BRAF | |
| SCHEMBL23081352 | 0.80 | BRAF (0.49) | BRAFFLT3AXLTYRO3MERTK | |
| SCHEMBL20003635 | 0.79 | MET (0.59) | BRAFFLT3AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20220324869-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324869-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | MET, MERTK, AXL | BRAF 18/4885FLT3 6/4885AXL 3/4885 |
| US-12479850-B2 | Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof | MET, MERTK, AXL | BRAF 18/4885FLT3 6/4885AXL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.